Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab for plasma cell targeting in ME/CFS (randomized placebo-controlled phase II)
2024-520094-13-00Phase 2Authorised
- Sponsor
- Helse Bergen
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myalgic encephalomyelitis (ME) comparing Daratumumab arm with Placebo arm (2 arms). Primary endpoint: Primary: DSQ-SF total score trajectory. Planned start May 2025; status: authorised.
02
Drugs
daratumumab
03
Conditions
myalgic encephalomyelitis (ME)
Beyond the preview
Go deeper on 2024-520094-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520094-13-00.